Sanofi Secures EU Approval For Cenrifki As First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses

뉴스 본문을 불러오고 있어요.

Sanofi Secures EU Approval For Cenrifki As First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses | 웨이프 WAPE

Sanofi Secures EU Approval For Cenrifki As First Disability-Targeting Medicine For Secondary Progressive Multiple Sclerosis Without Relapses

기사 요약

관련 종목

댓글 —